The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Multiple Myeloma in the Journal for ImmunoTherapy of Cancer on July 12, 2020. SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Multiple Myeloma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for FDA-approved immunotherapies for multiple myeloma, as well as discussion of promising emerging treatment modalities including chimeric antigen receptor T cell therapies and novel monoclonal antibody agents directed against B cell maturation antigen, and patient quality of life issues.
Published July 12, 2020 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma""
June 16, 2021, 5–6 pm ETCase Studies in Immunotherapy for the Treatment of Multiple Myeloma This high-level webinar is designed so that attendees will be able to execute the use of immunotherapy with increased confidence, plan management strategies for difficult cases, and identify and discuss areas of controversy in the immunotherapy field.Webinar Faculty:
Practical Management Pearls for Immunotherapy for the Treatment of Multiple MyelomaThis advanced webinar is designed for attendees to be able to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease, among other learning outcomes. SITC hosted this session on April 23, 2021, featuring members of the Cancer Immunotherapy Guidelines – Multiple Myeloma Expert Panel.VIEW ON-DEMAND WEBINAROverview of Immunotherapy for the Treatment of Multiple Myeloma Learn more about immunotherapy treatment standards for multiple myeloma and hear about the recently updated "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma" in this free one-hour webinar. SITC hosted this session on September 3, 2020, featuring members of the Cancer Immunotherapy Guidelines – Multiple Myeloma Expert Panel.VIEW ON-DEMAND WEBINAR
Jack Aiello, MS — Patient Advocate
David E. Avigan, MD — Beth Israel Deaconess Medical Center
Jesus G. Berdeja, MD — Sarah Cannon Research Institute
Ivan M. Borrello, MD — The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ajai Chari, MD — Icahn School of Medicine at Mount Sinai
Adam D. Cohen, MD — Abramson Cancer Center at the University of Pennsylvania
Karthik Ganapathi, MD — University of California San Francisco
Lissa Gray, FNP, MSN — University of California San Francisco
Damian Green, MD — Fred Hutchinson Cancer Research Center
Amrita Krishnan, MD — Judy and Bernard Briskin Multiple Myeloma Center for Clinical Research, City of Hope Comprehensive Cancer Center
Yi Lin, MD, PhD — Mayo Clinic
Elisabet Manasanch, MD, M.H.Sc. — The University of Texas MD Anderson Cancer Center
Nikhil C. Munshi, MD — Dana-Farber Cancer Institute
Ajay K. Nooka, MD, MPH, FACP — Emory University
Aaron P. Rapoport, MD — University of Maryland Greenebaum Comprehensive Cancer Center
Eric L. Smith, MD, PhD — Memorial Sloan Kettering Cancer Center
Ravi Vij, MD, MBA — Washington University School of Medicine in St. Louis
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com